| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) investing activities | -11,633 | -2,832 |
| Issuance of common stock from exercise of stock options and employee stock purchase plan purchases | 4,561 | 3,944 |
| Net cash provided by financing activities | 4,561 | 3,944 |
| Effect of exchange rates changes on cash, cash equivalents, and restricted cash | 441 | 474 |
| Net increase in cash, cash equivalents, and restricted cash | 88,642 | 53,645 |
| Cash and cash equivalents at beginning of period | 344,067 | - |
| Cash and cash equivalents at end of period | 432,709 | - |
10x Genomics, Inc. (TXG)
10x Genomics, Inc. (TXG)